Nvidia Plans Stakes in Doctolib, Genesis AI, Entalpic and Pigment as Europe Bet Nears €9 Billion
Nvidia plans minority investments in four French companies — medical booking platform Doctolib, robotics firm Genesis AI, materials specialist Entalpic and enterprise software company Pigment — as its European technology commitment nears nearly $10 billion, or about €9 billion, Euronews reported on October 14.
The bets sit inside a wider French push for AI sovereignty that accelerated after the February 2025 AI Action Summit and successive Choose France gatherings. Euronews noted that sovereignty, as the European Commission defines it, depends heavily on infrastructure now rising in western France, including Bull’s Angers plant that will integrate Foxconn-built trays and, from 2028, NVIDIA Vera Rubin Ultra NVL72 systems.
Nvidia also highlighted open-weight Nemotron models in production at French organisations that want data under domestic control, and pointed to Twake.ai from Linagora and Docaposte as the recommended sovereign workplace for more than 2,500 public bodies. Banking software group SBS is building a platform for in-house AI agents with Nvidia’s help, while Mistral’s open-weight Large 4 entered private preview last week.
What it means in practice
Capital from the dominant chip supplier into French application companies blurs the line between customer and partner, and it reinforces Paris’s wager that sovereignty means choosing partners rather than building every layer alone. It also echoes recent industrial moves such as the €47 million trusted AI cloud consortium around Cloud Temple, Thales, Bull, Vates and the CEA and Mistral Large 4’s open-weight release, while Inria’s €13.5 million evaluation and safety programme keeps pressure on measurement.
For hospitals booking through Doctolib, factories testing Genesis robots, labs using Entalpic’s materials models or finance teams on Pigment, the practical question is whether Nvidia equity comes with preferred access to scarce accelerators and engineering support. French officials will also watch whether open-weight deployments stay auditable under EU transparency rules.
What to watch: how large the four stakes are, whether Doctolib and Pigment keep European data residency as a selling point, and whether Bull’s Angers line hits its 2028 Rubin schedule.